Protocol Ledger

NCT06558799 · Phase II · TERMINATED

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Interventional Phase II clinical trial protocol NCT06558799 sponsored by NovoCure in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-14 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06558799
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06558799
Protocol FieldVerified Registry Value
NCT IdentifierNCT06558799
Consolidated Lead SponsorNovoCure
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2024-10-14
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06558799
Hospital Research SiteLocationSite Profile
Istituto Europeo di OncologiaMilan, ItalyOpen Hospital Dossier ->
Hospital Universitario Virgen del RocioSeville, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI